propranolol has been researched along with Disease Exacerbation in 57 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral propranolol reduces retinopathy of prematurity (ROP) progression, although not safely." | 9.24 | Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial. ( Agosti, M; Araimo, G; Bagnoli, P; Berti, E; Calvani, AM; Cavallaro, G; Cortinovis, I; Cristofori, G; Dal Monte, M; Della Bona, ML; Donzelli, G; Filippi, L; Fiorini, P; Fortunato, P; Fumagalli, M; la Marca, G; Milani, S; Mosca, F; Osnaghi, S; Padrini, L; Pasqualetti, R; Pugi, A; Tomasini, B; Vanni, M, 2017) |
| "To assess the effect of oral propranolol on the progression of early stages of retinopathy of prematurity (ROP) in very low birth weight (VLBW) infants." | 9.22 | Oral propranolol in early stages of retinopathy of prematurity. ( Bancalari, A; Lazcano, C; Muñoz, T; Parada, R; Peña, R; Schade, R, 2016) |
| "To study the clinical effectiveness of β-blocker therapy in patients with melanoma and to determine whether propranolol improves progression-free survival in patients with melanoma." | 7.88 | Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study. ( Benemei, S; Botteri, E; De Giorgi, V; Gandini, S; Geppetti, P; Grazzini, M; Marchionni, N; Pennacchioli, E, 2018) |
| "d-Propranolol (d-Pro: 2-8 mg·(kg body mass)(-1)·day(-1)) protected against cardiac dysfunction and oxidative stress during 3-5 weeks of iron overload (2 mg Fe-dextran·(g body mass)(-1)·week(-1)) in Sprague-Dawley rats." | 7.78 | d-Propranolol protects against oxidative stress and progressive cardiac dysfunction in iron overloaded rats. ( Chmielinska, JJ; Iantorno, M; Kramer, JH; Mak, IT; Spurney, CF; Tziros, C; Weglicki, WB, 2012) |
| " Data from the literature and from our own patient cohort (n = 132) confirm the remarkable efficacy of propranolol in complicated IH, without significant adverse effects." | 6.47 | [Treatment of haemangiomas of infancy with propranolol; good results, few side effects]. ( Hermans, DJ; Ottenhof, MJ; van Beynum, IM; van der Horst, CM; van der Vleuten, CJ; Wijnen, MH, 2011) |
| "Infantile haemangioma is a benign tumour of the microvasculature characterised by excessive proliferation of immature endothelial cells." | 5.37 | Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. ( Brasch, HD; Day, DJ; Itinteang, T; Tan, ST, 2011) |
| "We conducted a proof-of-concept randomized controlled pilot study assessing the feasibility of propranolol administration to patients between ages 18-75 who received an autologous HCT for multiple myeloma." | 5.27 | Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. ( Chhabra, S; Cole, SW; Costanzo, ES; D'Souza, A; Dhakal, B; Giles, KE; Hamadani, M; Hari, P; Horowitz, MM; Kerswill, SA; Knight, JM; Logan, BR; Rizzo, JD; Shah, NN; Sloan, EK; Stolley, MR, 2018) |
| "Oral propranolol reduces retinopathy of prematurity (ROP) progression, although not safely." | 5.24 | Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial. ( Agosti, M; Araimo, G; Bagnoli, P; Berti, E; Calvani, AM; Cavallaro, G; Cortinovis, I; Cristofori, G; Dal Monte, M; Della Bona, ML; Donzelli, G; Filippi, L; Fiorini, P; Fortunato, P; Fumagalli, M; la Marca, G; Milani, S; Mosca, F; Osnaghi, S; Padrini, L; Pasqualetti, R; Pugi, A; Tomasini, B; Vanni, M, 2017) |
| "To assess the effect of oral propranolol on the progression of early stages of retinopathy of prematurity (ROP) in very low birth weight (VLBW) infants." | 5.22 | Oral propranolol in early stages of retinopathy of prematurity. ( Bancalari, A; Lazcano, C; Muñoz, T; Parada, R; Peña, R; Schade, R, 2016) |
| " One week after starting propranolol treatment, all rats were submitted to chemical induction of oral carcinogenesis with 4-nitroquinoline-1-oxide (4NQO)." | 3.96 | Beta-adrenergic blocker inhibits oral carcinogenesis and reduces tumor invasion. ( Bernabé, DG; Biasoli, ÉR; Cecilio, HP; Furuse, C; Kayahara, GM; Miyahara, GI; Oliveira, SHP; Pereira, KM; Valente, VB, 2020) |
| "To study the clinical effectiveness of β-blocker therapy in patients with melanoma and to determine whether propranolol improves progression-free survival in patients with melanoma." | 3.88 | Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study. ( Benemei, S; Botteri, E; De Giorgi, V; Gandini, S; Geppetti, P; Grazzini, M; Marchionni, N; Pennacchioli, E, 2018) |
| "Propranolol could provide palliative effects in progression and survival of breast cancer that are mainly mediated via direct immunomodulatory and apoptotic mechanisms and probably associated with indirect anti-angiogenic activity." | 3.80 | Effect of propranolol on IL-10, visfatin, Hsp70, iNOS, TLR2, and survivin in amelioration of tumor progression and survival in Solid Ehrlich Carcinoma-bearing mice. ( Abdin, AA; Saied, EM; Soliman, NA, 2014) |
| "d-Propranolol (d-Pro: 2-8 mg·(kg body mass)(-1)·day(-1)) protected against cardiac dysfunction and oxidative stress during 3-5 weeks of iron overload (2 mg Fe-dextran·(g body mass)(-1)·week(-1)) in Sprague-Dawley rats." | 3.78 | d-Propranolol protects against oxidative stress and progressive cardiac dysfunction in iron overloaded rats. ( Chmielinska, JJ; Iantorno, M; Kramer, JH; Mak, IT; Spurney, CF; Tziros, C; Weglicki, WB, 2012) |
| " Although meta-analysis did not indicate a significant effect of beta-blockers on arterial hypotension or bradycardia, propranolol dosage in one study was reduced by 50% in infants of less than 26 weeks' gestational age due to severe hypotension, bradycardia, and apnoea in several participants." | 2.58 | Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants. ( Jost, K; Kaempfen, S; Neumann, RP; Schulzke, SM, 2018) |
| "Propranolol has recently been reported to be an effective and safe alternative." | 2.47 | The use of propranolol in the management of periocular capillary haemangioma--a systematic review. ( Reddy, AR; Spiteri Cornish, K, 2011) |
| " Data from the literature and from our own patient cohort (n = 132) confirm the remarkable efficacy of propranolol in complicated IH, without significant adverse effects." | 2.47 | [Treatment of haemangiomas of infancy with propranolol; good results, few side effects]. ( Hermans, DJ; Ottenhof, MJ; van Beynum, IM; van der Horst, CM; van der Vleuten, CJ; Wijnen, MH, 2011) |
| "Abdominal aortic aneurysm is a common condition that may be lethal when it is unrecognized." | 2.44 | Medical management of small abdominal aortic aneurysms. ( Baxter, BT; Dalman, RL; Terrin, MC, 2008) |
| "The propranolol +2DG treatment efficiently prevents prostate cancer cell proliferation, induces cell apoptosis, alters mitochondrial morphology, inhibits mitochondrial bioenergetics and aggravates ER stress in vitro and also suppresses tumor growth in vivo." | 1.48 | Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression. ( Brohée, L; Castronovo, V; Colige, AC; Deroanne, CF; Nusgens, B; Peulen, O; Thiry, M, 2018) |
| "Treatment with hydralazine at hypotensive dose for 12 weeks also failed to affect the proteinuria in 5 of 6 nephrectomized CKD rats." | 1.40 | Involvement of renal sympathetic nerve overactivation in the progression of chronic kidney disease in rats. ( Ayajiki, K; Funai, A; Kobuchi, S; Matsumura, Y; Ohkita, M; Suzuki, R; Tanaka, R; Tsutsui, H; Yazawa, M, 2014) |
| " Long exposures (24 h) in dose-response experiments with norepinephrine or epinephrine induced significant increases in DNA damage in treated cells compared to that of untreated controls as measured by the alkaline comet assay." | 1.39 | Chronic exposure to stress hormones promotes transformation and tumorigenicity of 3T3 mouse fibroblasts. ( Baum, A; Chambers, WH; Episcopo, B; Flint, MS; Jenkins, FJ; Knickelbein, KZ; Liegey Dougall, AJ, 2013) |
| "Infantile haemangioma is a benign tumour of the microvasculature characterised by excessive proliferation of immature endothelial cells." | 1.37 | Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. ( Brasch, HD; Day, DJ; Itinteang, T; Tan, ST, 2011) |
| "Propranolol users were significantly less likely to present with a T4 (odds ratio [OR], 0." | 1.37 | Beta blockers and breast cancer mortality: a population- based study. ( Barron, TI; Bennett, K; Connolly, RM; Sharp, L; Visvanathan, K, 2011) |
| "These included progressive supranuclear palsy (PSP; n = 2), drug-induced parkinsonism (n = 2), idiopathic Parkinson disease (PD; n = 1), and basal ganglia status cribrosus (n = 1)." | 1.32 | Essential tremor course and disability: A clinicopathologic study of 20 cases. ( Rajput, A; Rajput, AH; Robinson, CA, 2004) |
| " On the contrary, the chronic administration of corticosterone significantly induced the atrophy of thymus and spleen without affecting tumor growth." | 1.31 | Psychosocial stress augments tumor development through beta-adrenergic activation in mice. ( Hasegawa, H; Saiki, I, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.51) | 18.2507 |
| 2000's | 8 (14.04) | 29.6817 |
| 2010's | 39 (68.42) | 24.3611 |
| 2020's | 8 (14.04) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, SJ | 2 |
| Chang, HF | 1 |
| Qiu, Y | 4 |
| Chang, L | 3 |
| Jin, Y | 3 |
| Lin, X | 4 |
| Scaramuzzo, RT | 1 |
| Bagnoli, P | 2 |
| Dal Monte, M | 2 |
| Cammalleri, M | 1 |
| Pini, A | 1 |
| Ballini, S | 1 |
| Bendinelli, A | 1 |
| Desideri, I | 1 |
| Ciantelli, M | 1 |
| Filippi, L | 2 |
| Qiao, C | 2 |
| Gao, W | 2 |
| Ma, G | 2 |
| Stritzke, A | 1 |
| Kabra, N | 1 |
| Kaur, S | 1 |
| Robertson, HL | 1 |
| Lodha, A | 1 |
| Lim, TH | 1 |
| Yap, E | 1 |
| Norhatizah, BS | 1 |
| Lanfranconi, S | 1 |
| Scola, E | 1 |
| Bertani, GA | 1 |
| Zarino, B | 1 |
| Pallini, R | 1 |
| d'Alessandris, G | 1 |
| Mazzon, E | 1 |
| Marino, S | 1 |
| Carriero, MR | 1 |
| Scelzo, E | 1 |
| Faragò, G | 1 |
| Castori, M | 1 |
| Fusco, C | 1 |
| Petracca, A | 1 |
| d'Agruma, L | 1 |
| Tassi, L | 1 |
| d'Orio, P | 1 |
| Lampugnani, MG | 1 |
| Nicolis, EB | 1 |
| Vasamì, A | 1 |
| Novelli, D | 1 |
| Torri, V | 1 |
| Meessen, JMTA | 1 |
| Al-Shahi Salman, R | 1 |
| Dejana, E | 1 |
| Latini, R | 1 |
| Bancalari, A | 2 |
| Schade, R | 2 |
| Yang, J | 1 |
| Hyoju, SK | 1 |
| Zaborina, O | 1 |
| van Goor, H | 1 |
| Cecilio, HP | 1 |
| Valente, VB | 1 |
| Pereira, KM | 1 |
| Kayahara, GM | 1 |
| Furuse, C | 1 |
| Biasoli, ÉR | 1 |
| Miyahara, GI | 1 |
| Oliveira, SHP | 1 |
| Bernabé, DG | 1 |
| Huang, KY | 1 |
| Tseng, PT | 1 |
| Wu, YC | 1 |
| Tu, YK | 1 |
| Stubbs, B | 1 |
| Su, KP | 1 |
| Matsuoka, YJ | 1 |
| Hsu, CW | 1 |
| Lin, CH | 1 |
| Chen, YW | 1 |
| Lin, PY | 1 |
| De Giorgi, V | 1 |
| Grazzini, M | 1 |
| Benemei, S | 1 |
| Marchionni, N | 1 |
| Botteri, E | 1 |
| Pennacchioli, E | 1 |
| Geppetti, P | 1 |
| Gandini, S | 1 |
| Bishnu, S | 1 |
| Ahammed, SM | 1 |
| Sarkar, A | 1 |
| Hembram, J | 1 |
| Chatterjee, S | 1 |
| Das, K | 2 |
| Dhali, GK | 1 |
| Chowdhury, A | 1 |
| Zhang, L | 1 |
| Fang, Y | 1 |
| Cheng, X | 1 |
| Lian, Y | 1 |
| Xu, H | 1 |
| Zeng, Z | 1 |
| Zhu, H | 1 |
| Kaempfen, S | 1 |
| Neumann, RP | 1 |
| Jost, K | 1 |
| Schulzke, SM | 1 |
| Brohée, L | 1 |
| Peulen, O | 1 |
| Nusgens, B | 1 |
| Castronovo, V | 1 |
| Thiry, M | 1 |
| Colige, AC | 1 |
| Deroanne, CF | 1 |
| Knight, JM | 1 |
| Kerswill, SA | 1 |
| Hari, P | 1 |
| Cole, SW | 2 |
| Logan, BR | 1 |
| D'Souza, A | 1 |
| Shah, NN | 1 |
| Horowitz, MM | 1 |
| Stolley, MR | 1 |
| Sloan, EK | 2 |
| Giles, KE | 1 |
| Costanzo, ES | 1 |
| Hamadani, M | 1 |
| Chhabra, S | 1 |
| Dhakal, B | 1 |
| Rizzo, JD | 1 |
| Bührer, C | 1 |
| Erdeve, Ö | 1 |
| Bassler, D | 1 |
| Bar-Oz, B | 1 |
| Montnach, J | 1 |
| Chizelle, FF | 1 |
| Belbachir, N | 1 |
| Castro, C | 1 |
| Li, L | 1 |
| Loussouarn, G | 1 |
| Toumaniantz, G | 1 |
| Carcouët, A | 1 |
| Meinzinger, AJ | 1 |
| Shmerling, D | 1 |
| Benitah, JP | 1 |
| Gómez, AM | 1 |
| Charpentier, F | 1 |
| Baró, I | 1 |
| O'Brien, KF | 1 |
| Shah, SD | 1 |
| Pope, E | 1 |
| Phillips, RJ | 2 |
| Blei, F | 1 |
| Baselga, E | 1 |
| Garzon, MC | 1 |
| McCuaig, C | 1 |
| Haggstrom, AN | 1 |
| Hoeger, PH | 1 |
| Treat, JR | 1 |
| Perman, MJ | 1 |
| Bellet, JS | 1 |
| Cubiró, X | 1 |
| Poole, J | 1 |
| Frieden, IJ | 1 |
| Martin, JM | 1 |
| Sanchez, S | 1 |
| González, V | 1 |
| Cordero, P | 1 |
| Ramon, D | 1 |
| Yang, K | 1 |
| Feng, L | 1 |
| Chen, S | 1 |
| Ji, Y | 1 |
| Yu, Z | 1 |
| Cai, R | 1 |
| Chen, X | 1 |
| Chen, Q | 1 |
| Zaghloul, SG | 1 |
| Wahab, EA | 1 |
| Seleem, WM | 1 |
| Hanafy, AS | 1 |
| Gomaa, AF | 1 |
| Lakouz, K | 1 |
| Amin, AI | 1 |
| Kao, J | 1 |
| Luu, B | 1 |
| Elshershari, H | 1 |
| Harris, C | 1 |
| Kobuchi, S | 1 |
| Tanaka, R | 1 |
| Funai, A | 1 |
| Suzuki, R | 1 |
| Yazawa, M | 1 |
| Tsutsui, H | 1 |
| Ohkita, M | 1 |
| Ayajiki, K | 1 |
| Matsumura, Y | 1 |
| Fitzgerald, PJ | 1 |
| Abdin, AA | 1 |
| Soliman, NA | 1 |
| Saied, EM | 1 |
| Korsaga-Somé, N | 1 |
| Maruani, A | 1 |
| Abdo, I | 1 |
| Favrais, G | 1 |
| Lorette, G | 1 |
| Muñoz, T | 1 |
| Lazcano, C | 1 |
| Parada, R | 1 |
| Peña, R | 1 |
| Reinhard, M | 1 |
| Schuchardt, F | 1 |
| Meckel, S | 1 |
| Heinz, J | 1 |
| Felbor, U | 1 |
| Sure, U | 1 |
| Geisen, U | 1 |
| Duff, S | 1 |
| Connolly, C | 1 |
| Buggy, DJ | 1 |
| Cavallaro, G | 1 |
| Fiorini, P | 1 |
| Berti, E | 1 |
| Padrini, L | 1 |
| Donzelli, G | 1 |
| Araimo, G | 1 |
| Cristofori, G | 1 |
| Fumagalli, M | 1 |
| la Marca, G | 1 |
| Della Bona, ML | 1 |
| Pasqualetti, R | 1 |
| Fortunato, P | 1 |
| Osnaghi, S | 1 |
| Tomasini, B | 1 |
| Vanni, M | 1 |
| Calvani, AM | 1 |
| Milani, S | 1 |
| Cortinovis, I | 1 |
| Pugi, A | 1 |
| Agosti, M | 1 |
| Mosca, F | 1 |
| Crock, CM | 1 |
| Penington, AJ | 1 |
| Bekhor, PS | 1 |
| Ma, LJ | 1 |
| You, Y | 1 |
| Bai, BX | 1 |
| Li, YZ | 1 |
| Buckmiller, L | 1 |
| Dyamenahalli, U | 1 |
| Richter, GT | 1 |
| Sangla, S | 1 |
| Tranchant, C | 1 |
| Itinteang, T | 1 |
| Brasch, HD | 1 |
| Tan, ST | 1 |
| Day, DJ | 1 |
| Claerhout, I | 1 |
| Buijsrogge, M | 1 |
| Delbeke, P | 1 |
| Walraedt, S | 1 |
| De Schepper, S | 1 |
| De Moerloose, B | 1 |
| De Groote, K | 1 |
| Decock, C | 1 |
| McMurray, JJ | 1 |
| Schöni, MH | 1 |
| Kernland Lang, K | 1 |
| Barron, TI | 1 |
| Connolly, RM | 1 |
| Sharp, L | 1 |
| Bennett, K | 1 |
| Visvanathan, K | 1 |
| Spiteri Cornish, K | 1 |
| Reddy, AR | 1 |
| Hermans, DJ | 1 |
| Ottenhof, MJ | 1 |
| Wijnen, MH | 1 |
| van Beynum, IM | 1 |
| van der Horst, CM | 1 |
| van der Vleuten, CJ | 1 |
| Lamkin, DM | 1 |
| Patel, AJ | 1 |
| Chiang, BS | 1 |
| Pimentel, MA | 1 |
| Ma, JC | 1 |
| Arevalo, JM | 1 |
| Morizono, K | 1 |
| Flint, MS | 1 |
| Baum, A | 1 |
| Episcopo, B | 1 |
| Knickelbein, KZ | 1 |
| Liegey Dougall, AJ | 1 |
| Chambers, WH | 1 |
| Jenkins, FJ | 1 |
| Assar, AN | 1 |
| Kramer, JH | 1 |
| Spurney, CF | 1 |
| Iantorno, M | 1 |
| Tziros, C | 1 |
| Chmielinska, JJ | 1 |
| Mak, IT | 1 |
| Weglicki, WB | 1 |
| Salazar-Murillo, R | 1 |
| García-Pacheco, S | 1 |
| González-Blanco, MJ | 1 |
| Bolívar-Montesa, P | 1 |
| Campos-García, S | 1 |
| Hasegawa, H | 1 |
| Saiki, I | 1 |
| Rajput, A | 1 |
| Robinson, CA | 1 |
| Rajput, AH | 1 |
| Silberstein, SD | 1 |
| Lee, S | 1 |
| Tsirbas, A | 1 |
| Goldberg, RA | 1 |
| McCann, JD | 1 |
| Baxter, BT | 1 |
| Terrin, MC | 1 |
| Dalman, RL | 1 |
| Cronenwett, JL | 1 |
| Ricci, MA | 1 |
| Pilcher, DB | 1 |
| McBride, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treat_CCM Clinical Trial A Multicenter Randomized Clinical Trial on Propranolol in Familial Cerebral Cavernous Malformation[NCT03589014] | Phase 2 | 71 participants (Actual) | Interventional | 2018-04-11 | Completed | ||
| Randomized Controlled Pilot Study Using Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in Hematopoietic Stem Cell Transplant (HCT) Recipients[NCT02420223] | Phase 2 | 25 participants (Actual) | Interventional | 2015-07-17 | Completed | ||
| Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity[NCT03083431] | Phase 2 | 276 participants (Anticipated) | Interventional | 2022-09-22 | Recruiting | ||
| Improving Perioperative Pain Management for Laparoscopic Surgery Due to Colon Cancer Using the Ultrasound-guided Transmuscular Quadratus Lumborum Block. A Double Blind, Randomized, Placebo Controlled Trial.[NCT03570541] | Phase 4 | 69 participants (Actual) | Interventional | 2018-06-28 | Completed | ||
| Anesthesia and Immunological and Oxidative Stress in Relation to Abdominal Cancer Surgery[NCT03974984] | 0 participants (Actual) | Observational | 2020-06-04 | Withdrawn (stopped due to Not feasable due to logistics) | |||
| Impact of Novel Thoracic Wall Blocks With Dexmetomidine on Inflammatory Markers Following Breast Cancer Surgery[NCT04860115] | 120 participants (Anticipated) | Interventional | 2021-11-01 | Not yet recruiting | |||
| Safety and Efficacy of Propranolol Eye Drops in Newborns With Retinopathy of Premature (DROP-PROP)[NCT02014454] | Phase 2 | 23 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Melablock: A Multicentre Randomized, Double---blinded and Placebo---controlled Clinical Trial on the Efficacy and Safety of Once Daily Propranolol 80 mg Retard for the Prevention of Cutaneous Malignant Melanoma Recurrence[NCT02962947] | Phase 2/Phase 3 | 546 participants (Anticipated) | Interventional | 2017-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Expression (up or down regulation) of genes involved in the stress response can be modulated through the beta-adrenergic pathway. The log2 RNA abundance is a means to normalize results to determine whether a gene is up regulated (value greater than 1) or down regulated (value less than 1). Differential change in log2 RNA abundance is defined by the fold change (FC) as log2FC=Log2(B)-Log2(A). Logarithmic measures are unitless. The change in the measure between two time points determines whether a gene has up-or down-regulated. (NCT02420223)
Timeframe: Baseline (Pre-Transplant); 4 weeks post-transplant
| Intervention | Unitless (Mean) |
|---|---|
| Propranolol | -0.407 |
| Control Arm | 0.0099 |
This measure is the number of subjects diagnosed with culture-positive infection or neutropenic fever greater than 100.4 degrees Fahrenheit. (NCT02420223)
Timeframe: Up to 100 days after transplant
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 1 |
| Control Arm | 6 |
Number of subjects experiencing any of: fever, diarrhea or rash requiring steroid intervention within 48 hours before or after neutrophil recovery. (NCT02420223)
Timeframe: 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 6 |
| Control Arm | 3 |
This measure is the mean time to the beginning of three consecutive days where the neutrophil count (absolute neutrophil count) was 500 cells/mm^3 (0.5 x 10^9/L) or greater. (NCT02420223)
Timeframe: 4 weeks after transplant
| Intervention | Days (Mean) |
|---|---|
| Propranolol | 10.5 |
| Control Arm | 11.9 |
This measure is the mean time to the beginning of three consecutive days where the platelet count is at least 20,000/mm^3 (20 x 10^9/L) unsupported by a platelet transfusion. (NCT02420223)
Timeframe: 4 weeks
| Intervention | Days (Mean) |
|---|---|
| Propranolol | 16.6 |
| Control Arm | 19.6 |
This measure is the number of participants experiencing a response defined by the International Uniform Response Criteria as: very good partial response (VGPR) or better (near complete response (nCR), complete response (CR), and stringent CR (sCR) according to at day 100 post-Hematopoietic Cell Transplant. (NCT02420223)
Timeframe: 100 days after transplant
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Stable Disease | Partial Response | Very Good Partial Response | Complete Response | |
| Control Arm | 0 | 5 | 5 | 3 |
| Propranolol | 1 | 5 | 5 | 1 |
This measure will be assessed using the Hospital Anxiety and Depression Scale (HADS). The HADS scale includes fourteen 4-response Likert-scale questions graded 0 to 3. Seven questions are specific to depression; 7 questions are specific to anxiety. The score is the total of the responses in their respective categories. Lower scores indicated less depression and/or anxiety. Scores 0-7 indicate normal status; scores 8-10 suggest borderline abnormal status; and scores 11-21 indicate abnormal status. Only anxiety scores are presented. (NCT02420223)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline Anxiety Score | 4-Week Anxiety Score | |
| Control Arm | 7.4 | 5.2 |
| Propranolol | 7.3 | 4.4 |
14 reviews available for propranolol and Disease Exacerbation
| Article | Year |
|---|---|
Oral propranolol in prevention of severe retinopathy of prematurity: a systematic review and meta-analysis.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Disease Progression; Humans; Infant, Newborn; Inf | 2019 |
Update in the Treatment of Retinopathy of Prematurity.
Topics: Adrenergic beta-Antagonists; Bevacizumab; Disease Progression; Humans; Infant, Newborn; Infant, Prem | 2022 |
Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Cardiovascular Diseases; Ce | 2021 |
Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Cryotherapy; Disease Progression; Humans; Infa | 2018 |
Can propranolol prevent progression of melanoma?
Topics: Adrenergic beta-Antagonists; Disease Progression; Humans; Melanoma; Neoplasm Recurrence, Local; Prop | 2019 |
Adrenergic, Inflammatory, and Immune Function in the Setting of Oncological Surgery: Their Effects on Cancer Progression and the Role of the Anesthetic Technique in their Modulation.
Topics: Adrenergic beta-Antagonists; Anesthesia; Anesthetics; Animals; Disease Models, Animal; Disease Progr | 2016 |
Adrenergic, Inflammatory, and Immune Function in the Setting of Oncological Surgery: Their Effects on Cancer Progression and the Role of the Anesthetic Technique in their Modulation.
Topics: Adrenergic beta-Antagonists; Anesthesia; Anesthetics; Animals; Disease Models, Animal; Disease Progr | 2016 |
Adrenergic, Inflammatory, and Immune Function in the Setting of Oncological Surgery: Their Effects on Cancer Progression and the Role of the Anesthetic Technique in their Modulation.
Topics: Adrenergic beta-Antagonists; Anesthesia; Anesthetics; Animals; Disease Models, Animal; Disease Progr | 2016 |
Adrenergic, Inflammatory, and Immune Function in the Setting of Oncological Surgery: Their Effects on Cancer Progression and the Role of the Anesthetic Technique in their Modulation.
Topics: Adrenergic beta-Antagonists; Anesthesia; Anesthetics; Animals; Disease Models, Animal; Disease Progr | 2016 |
Adrenergic, Inflammatory, and Immune Function in the Setting of Oncological Surgery: Their Effects on Cancer Progression and the Role of the Anesthetic Technique in their Modulation.
Topics: Adrenergic beta-Antagonists; Anesthesia; Anesthetics; Animals; Disease Models, Animal; Disease Progr | 2016 |
Adrenergic, Inflammatory, and Immune Function in the Setting of Oncological Surgery: Their Effects on Cancer Progression and the Role of the Anesthetic Technique in their Modulation.
Topics: Adrenergic beta-Antagonists; Anesthesia; Anesthetics; Animals; Disease Models, Animal; Disease Progr | 2016 |
Adrenergic, Inflammatory, and Immune Function in the Setting of Oncological Surgery: Their Effects on Cancer Progression and the Role of the Anesthetic Technique in their Modulation.
Topics: Adrenergic beta-Antagonists; Anesthesia; Anesthetics; Animals; Disease Models, Animal; Disease Progr | 2016 |
Adrenergic, Inflammatory, and Immune Function in the Setting of Oncological Surgery: Their Effects on Cancer Progression and the Role of the Anesthetic Technique in their Modulation.
Topics: Adrenergic beta-Antagonists; Anesthesia; Anesthetics; Animals; Disease Models, Animal; Disease Progr | 2016 |
Adrenergic, Inflammatory, and Immune Function in the Setting of Oncological Surgery: Their Effects on Cancer Progression and the Role of the Anesthetic Technique in their Modulation.
Topics: Adrenergic beta-Antagonists; Anesthesia; Anesthetics; Animals; Disease Models, Animal; Disease Progr | 2016 |
[Writer's cramp].
Topics: Botulinum Toxins, Type A; Clonazepam; Combined Modality Therapy; Cumulative Trauma Disorders; Diagno | 2009 |
The use of propranolol in the treatment of periocular infantile haemangiomas: a review.
Topics: Adrenergic beta-Antagonists; Disease Progression; Eye Neoplasms; Hemangioma, Capillary; Humans; Infa | 2011 |
The use of propranolol in the management of periocular capillary haemangioma--a systematic review.
Topics: Administration, Oral; Antineoplastic Agents; Child, Preschool; Disease Progression; Evidence-Based M | 2011 |
[Treatment of haemangiomas of infancy with propranolol; good results, few side effects].
Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Disease Progression; Hemangioma; Humans; Infan | 2011 |
Medical treatment of small abdominal aortic aneurysm.
Topics: Aortic Aneurysm, Abdominal; Cardiovascular Agents; Disease Progression; Doxycycline; Humans; Hydroxy | 2012 |
Preventive treatment of headaches.
Topics: Acupuncture Therapy; Adrenergic beta-Antagonists; Anticonvulsants; Disease Progression; Fructose; Hu | 2005 |
Medical management of small abdominal aortic aneurysms.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Variables that affect the expansion rate and rupture of abdominal aortic aneurysms.
Topics: Adrenergic beta-Antagonists; Aortic Aneurysm, Abdominal; Aortic Rupture; Comorbidity; Diastole; Dise | 1996 |
7 trials available for propranolol and Disease Exacerbation
| Article | Year |
|---|---|
Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial.
Topics: Adrenergic beta-Antagonists; Adult; Animals; Anxiety; Case-Control Studies; Depression; Disease Prog | 2020 |
Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atorvastatin; Disease Progression; Drug | 2018 |
Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Chemotherapy, Adjuvant; Disease Progression; Drug Repositi | 2018 |
Oral propranolol for prevention of threshold retinopathy of prematurity (ROPROP): protocol of a randomised controlled trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Disease Progression; Double-Blind Method; Gestati | 2018 |
Oral propranolol in early stages of retinopathy of prematurity.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Bevacizumab; Disease Pro | 2016 |
Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial.
Topics: Administration, Ophthalmic; Administration, Oral; Administration, Topical; Disease Progression; Fema | 2017 |
Design of a trial to evaluate the effect of propranolol upon abdominal aortic aneurysm expansion.
Topics: Adrenergic beta-Antagonists; Aortic Aneurysm, Abdominal; Aortic Rupture; Disease Progression; Double | 1996 |
36 other studies available for propranolol and Disease Exacerbation
| Article | Year |
|---|---|
Does Oral Propranolol Improve the Final Outcome of All Involuted Infantile Hemangiomas? A Matched Retrospective Comparative Study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Disease Progression; Hemangioma; Hemangioma, Capi | 2022 |
Treating infants with 0.2% propranolol eye micro-drops drastically reduced the progression of retinopathy of prematurity.
Topics: Disease Progression; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; In | 2023 |
A 7-year follow-up study on untreated deep or mixed facial infantile hemangioma in East-Asian patients: When propranolol was not yet an option.
Topics: Asian People; Cardiovascular Agents; Child; Child, Preschool; Conservative Treatment; Disease Progre | 2019 |
Facial segmental haemangioma with PHACE Syndrome successfully treated with oral propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aortic Coarctation; Disease Progression; Eye Abno | 2019 |
Successful treatment of infantile hemangioma with high risk of severe sequelae by microneedle radiofrequency.
Topics: Disease Progression; Hemangioma; Humans; Infant; Propranolol | 2020 |
SARS-CoV-2 and the sympathetic immune response: Dampening inflammation with antihypertensive drugs (Clonidine and Propranolol).
Topics: Antihypertensive Agents; Antiviral Agents; Clonidine; Comorbidity; COVID-19; Disease Progression; Hu | 2020 |
Beta-adrenergic blocker inhibits oral carcinogenesis and reduces tumor invasion.
Topics: 4-Nitroquinoline-1-oxide; Adrenergic beta-Antagonists; Animals; Carcinogenesis; Carcinogens; Cytokin | 2020 |
Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study.
Topics: Aged; Cohort Studies; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Mi | 2018 |
TRPML1 Participates in the Progression of Alzheimer's Disease by Regulating the PPARγ/AMPK/Mtor Signalling Pathway.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Amyloid beta-Peptides; Amyloid beta-Protein Precur | 2017 |
Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression.
Topics: Animals; Autophagy; Carbohydrate Metabolism; Cell Line, Tumor; Disease Models, Animal; Disease Progr | 2018 |
Arrhythmias precede cardiomyopathy and remodeling of Ca
Topics: Action Potentials; Animals; Calcium; Cardiomyopathies; Disease Models, Animal; Disease Progression; | 2018 |
Late growth of infantile hemangiomas in children >3 years of age: A retrospective study.
Topics: Adrenal Cortex Hormones; Age Factors; Child; Child, Preschool; Cohort Studies; Disease Progression; | 2019 |
Infantile hemangiomas with minimal or arrested growth: A retrospective case series.
Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Disease Progression; Female; Hemangioma; Human | 2019 |
Progressive infantile hepatic hemangioma not responding to propranolol.
Topics: Adrenergic beta-Antagonists; Age of Onset; Child, Preschool; Disease Progression; Fatal Outcome; Fem | 2019 |
Clinical and radiological outcomes of infantile hemangioma treated with oral propranolol: A long-term follow-up study.
Topics: Administration, Oral; Child, Preschool; Disease Progression; Erythema; Female; Follow-Up Studies; He | 2019 |
Impact of non-selective beta blockers on portal hypertension and hepatic elasticity in hepatitis C virus-related liver cirrhosis.
Topics: Adrenergic beta-Antagonists; Case-Control Studies; Disease Progression; Elasticity Imaging Technique | 2019 |
Paternal fibrillin-1 mutation transmitted to an affected son with neonatal marfan syndrome: the importance of early recognition.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Dilatation, Pathologic; | 2014 |
Involvement of renal sympathetic nerve overactivation in the progression of chronic kidney disease in rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Autonom | 2014 |
Is elevated norepinephrine an etiological factor in some cases of Parkinson's disease?
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Disease Progression; Humans; Mice; Models, Theoret | 2014 |
Effect of propranolol on IL-10, visfatin, Hsp70, iNOS, TLR2, and survivin in amelioration of tumor progression and survival in Solid Ehrlich Carcinoma-bearing mice.
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Breast Neoplasms; Carcinoma, Ehrlich Tumor; Disease | 2014 |
[Kasabach-Merritt phenomenon (KMP) exacerbated by platelet transfusions].
Topics: Aspirin; Axilla; Combined Modality Therapy; Compression Bandages; Disease Progression; Disseminated | 2015 |
Propranolol stops progressive multiple cerebral cavernoma in an adult patient.
Topics: Brain; Disease Progression; Follow-Up Studies; Hemangioma, Cavernous, Central Nervous System; Humans | 2016 |
Prolonged tumour growth after treatment of infantile haemangioma with propranolol.
Topics: Child; Child, Preschool; Disease Progression; Female; Hemangioma; Humans; Infant; Infant, Newborn; M | 2017 |
Therapeutic effects of heme oxygenase-1 on psoriasiform skin lesions in guinea pigs.
Topics: Animals; Disease Models, Animal; Disease Progression; Enzyme Activation; Gene Expression Regulation; | 2009 |
Propranolol for airway hemangiomas: case report of novel treatment.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents, Phytogenic; Bronchoscopy; Disease Progression; F | 2009 |
Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution.
Topics: Adrenergic beta-Antagonists; Angiotensins; Biomarkers, Tumor; Cell Proliferation; Disease Progressio | 2011 |
Heart failure: acute ischemic events in HF--should we include sudden death?
Topics: Adrenergic beta-1 Receptor Antagonists; Antihypertensive Agents; Benzopyrans; Death, Sudden, Cardiac | 2011 |
[Hemangiomas in childhood].
Topics: Adrenergic beta-Antagonists; Disease Progression; Female; Hemangioma; Hemangioma, Cavernous; Humans; | 2011 |
Beta blockers and breast cancer mortality: a population- based study.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Breast Neoplasms; Disease Progression; Female; Humans; | 2011 |
Chronic stress enhances progression of acute lymphoblastic leukemia via β-adrenergic signaling.
Topics: Adrenergic beta-Antagonists; Animals; Cell Line, Tumor; Cyclic AMP; Disease Models, Animal; Disease | 2012 |
Chronic exposure to stress hormones promotes transformation and tumorigenicity of 3T3 mouse fibroblasts.
Topics: Adrenergic beta-Antagonists; Animals; Carcinogenicity Tests; Cell Transformation, Neoplastic; Comet | 2013 |
d-Propranolol protects against oxidative stress and progressive cardiac dysfunction in iron overloaded rats.
Topics: Acetylglucosaminidase; Adrenergic beta-Antagonists; Animals; Cardiac Output; Disease Progression; Do | 2012 |
[Propranolol: Treatment of capillary hemangioma with orbital involvement].
Topics: Disease Progression; Eyelid Neoplasms; Facial Neoplasms; Female; Hemangioma, Capillary; Humans; Infa | 2012 |
Psychosocial stress augments tumor development through beta-adrenergic activation in mice.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Anti-Inflammatory Agents; Cell Division; | 2002 |
Essential tremor course and disability: A clinicopathologic study of 20 cases.
Topics: Adrenergic beta-Antagonists; Age of Onset; Aged; Antiparkinson Agents; Disability Evaluation; Diseas | 2004 |
Thiazolidinedione induced thyroid associated orbitopathy.
Topics: Diplopia; Disease Progression; Drug Therapy, Combination; Exophthalmos; Female; Graves Ophthalmopath | 2007 |